Ocugen, Inc. (OCGN) CEO Shankar Musunuri on Q1 2022 Results - Earnings Call Transcript

May 06, 2022 8:56 PM ETOcugen, Inc. (OCGN)
SA Transcripts profile picture
SA Transcripts
133.67K Followers

Ocugen, Inc. (NASDAQ:OCGN) Q1 2022 Earnings Conference Call May 6, 2022 8:30 AM ET

Company Participants

Ken Inchausti - Head, Investor Relations & Communications

Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder

Jessica Crespo - Chief Accounting Officer & Senior Vice President, Finance

Conference Call Participants

Zegbeh Jallah - ROTH Capital Partners

Swayampakula Ramakanth - H.C. Wainwright

Operator

Good morning, and welcome to the Ocugen Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the presentation. [Operator instructions] Please note, this conference is being recorded.

I will now turn the conference over to Ken Inchausti, Head of Investor Relations and Communications for Ocugen. You may begin.

Ken Inchausti

Thank you, operator. I'd like to welcome you to our conference call. With me today are Ocugen's Chairman and CEO and Co-Founder, Dr. Shankar Musunuri, who will provide a business update and our Chief Accounting Officer and Senior Vice President of Finance, Jessica Crespo, who will provide a financial update.

Earlier this morning, we issued a press release, including a business update and first-quarter financial results for 2022. We encourage listeners to review the press release, which is available on our website at www.ocugen.com. This call is also being recorded and a replay along with accompanying slides will be available on the Investors' section of the Ocugen website for approximately 45 days.

As always, we need to advise you that this call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations including among other things; the uncertainties inherent in research and development of our product candidates; risks to our business related to the ongoing COVID-19 pandemic; uncertainty regarding whether and when we will be able to submit a biologics license application for Covaxin to

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.